Losartan Potassium
Product Images NDC 53808-0892

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 53808-0892). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label Image For 25mg (25mg Qualitest)

Label Image For 25mg (25mg Qualitest)
Losartan potassium is a medication available in tablet form with a strength of 25mg. This is a prescription-only medication and the quantity provided is 30 tablets. It is manufactured by Qualitest and has the lot number 1205004315. The package of the medication was produced on 2nd December 2013 and expiry date of the medication is 31st August 2013. The medication was packaged by DOH Central Pharmacy located in Taliahassee, FL 32304. The provided UPC code is 306034224321.*
FDA Label Image

Label Image For 50mg (50mg Qualitest)

Label Image For 50mg (50mg Qualitest)
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
This text is a combination of a medicine's name (Atenolol) and another medicine's name (Losartan Potassium Tablets), followed by a graph with a horizontal axis showing different study months and a vertical axis showing an adjusted risk reduction percentage of 13%. Without context it is difficult to say what the graph is representing.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
The text is describing subgroups and their respective stroke rates based on a study that evaluated the effectiveness of Losartan potassium tablets compared to Alenolol tablets. The subgroups analyzed include age range, gender, race, history of CVD, and presence of diabetes. The table shows the number of events, rates, hazard ratios, and confidence intervals for each subgroup. The results are adjusted for baseline Framingham risk score and level of slectrocardiographic ef ventricular hypertrophy. The text also clarifies that "Other" includes individuals of Asian, Hispanic, Pacific Islander, Native American, and European descent.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
This text describes a study on the effectiveness of Losartan Potassium Tablets in reducing the risk of an event in patients. The study found that 9% of patients experienced an event, and that the use of Losartan Potassium Tablets reduced the risk of an event by 16.1% compared to a placebo. The study was conducted over a period of 12, 24, 36, and 48 months.*
FDA Label Image

Structure-losartan Potassium (Structure)

Structure-losartan Potassium (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.